OpenURL Connection Search

Select item for more details and to access through your institution.

Cluster-10 lung-cancer antibodies recognize NSPs, novel neuro-endocrine proteins associated with membranes of the endoplasmic reticulum.
Published in:
International Journal of Cancer, 1994, v. 57, p. 84, doi. 10.1002/ijc.2910570718
By:
- Senden, Nicole H. M.;
- Van De Velde, Helgi J. K.;
- Broers, Jos L. V.;
- Timmer, Erika D. J.;
- Roebroek, Anton J. M.;
- Van De Ven, Wim J. M.;
- Ramaekers, Frans C. S.
Publication type:
Article
A COMPARISON OF NSP-RETICULONS WITH CONVENTIONAL NEUROENDOCRINE MARKERS IN IMMUNOPHENOTYPING OF LUNG CANCERS.
Published in:
Journal of Pathology, 1997, v. 182, n. 1, p. 13, doi. 10.1002/(SICI)1096-9896(199705)182:1<13::AID-PATH804>3.0.CO;2-Z
By:
- SENDEN, NICOLE H. M.;
- TIMMER, ERIKA D. J.;
- DE BRUÏNE, ADRIAAN;
- WAGENAAR, SJOERD SC.;
- VAN DE VELDE, HELGI J. K.;
- ROEBROEK, ANTON J. M.;
- VAN DE VEN, WIM J. M.;
- BROERS, JOS L. V.;
- RAMAEKERS, FRANS C. S.
Publication type:
Article
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres.
Published in:
British Journal of Haematology, 2014, v. 165, n. 1, p. 39, doi. 10.1111/bjh.12717
By:
- Robinson, Don;
- Reynolds, Matthew;
- Casper, Corey;
- Dispenzieri, Angela;
- Vermeulen, Jessica;
- Payne, Krista;
- Schramm, Judy;
- Ristow, Kay;
- Desrosiers, Marie‐Pierre;
- Yeomans, Karen;
- Teltsch, Dana;
- Swain, Richard;
- Habermann, Thomas M.;
- Rotella, Philip;
- Van de Velde, Helgi
Publication type:
Article
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Published in:
Investigational New Drugs, 2018, v. 36, n. 4, p. 619, doi. 10.1007/s10637-017-0531-3
By:
- Bahleda, Rastislav;
- Le Deley, Marie-Cécile;
- Bernard, Apexa;
- Chaturvedi, Shalini;
- Hanley, Michael;
- Poterie, Audrey;
- Gazzah, Anas;
- Varga, Andreea;
- Touat, Mehdi;
- Deutsch, Eric;
- Massard, Christophe;
- Van De Velde, Helgi;
- Hollebecque, Antoine;
- Sallansonnet-Froment, Magali;
- Ricard, Damien;
- Taillia, Hervé;
- Angevin, Eric;
- Ribrag, Vincent;
- Soria, Jean-Charles
Publication type:
Article
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis.
Published in:
American Journal of Hematology, 2021, v. 96, n. 11, p. E423, doi. 10.1002/ajh.26319
By:
- Schjesvold, Fredrik;
- Bringhen, Sara;
- G. Richardson, Paul;
- Perrot, Aurore;
- Leleu, Xavier;
- Moreau, Philippe;
- A. Dimopoulos, Meletios;
- Hulin, Cyrille;
- Tekle, Christina;
- Foster, Meredith C.;
- Poole, Elizabeth M.;
- van de Velde, Helgi;
- Facon, Thierry
Publication type:
Article
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Published in:
2016
By:
- Mateos, Maria-Victoria;
- Oriol, Albert;
- Martínez-López, Joaquín;
- Teruel, Ana-Isabel;
- Bengoechea, Enrique;
- Palomera, Luis;
- de Arriba, Felipe;
- Esseltine, Dixie-Lee;
- Cakana, Andrew;
- Pei, Lixia;
- van de Velde, Helgi;
- Miguel, Jesus;
- Martínez-López, Joaquín;
- Miguel, Jesus San
Publication type:
journal article
Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
Published in:
British Journal of Clinical Pharmacology, 2022, v. 88, n. 5, p. 2052, doi. 10.1111/bcp.15123
By:
- Thai, Hoai‐Thu;
- Gaudel, Nadia;
- Cerou, Marc;
- Ayral, Geraldine;
- Fau, Jean‐Baptiste;
- Sebastien, Bernard;
- van de Velde, Helgi;
- Semiond, Dorothée;
- Veyrat‐Follet, Christine
Publication type:
Article
An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Published in:
European Journal of Haematology, 2024, v. 113, n. 5, p. 593, doi. 10.1111/ejh.14270
By:
- Kapoor, Prashant;
- Nathwani, Nitya;
- Jelinek, Tomas;
- Pour, Ludek;
- Perrot, Aurore;
- Dimopoulos, Meletios‐Athanasios;
- Huang, Shang‐Yi;
- Spicka, Ivan;
- Chhabra, Saurabh;
- Lichtman, Eben;
- Mateos, Maria‐Victoria;
- Kanagavel, Dheepak;
- Zhao, Liang;
- Guillemin‐Paveau, Helene;
- Macé, Sandrine;
- van de Velde, Helgi;
- Richardson, Paul G.
Publication type:
Article
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis.
Published in:
European Journal of Haematology, 2022, v. 109, n. 5, p. 504, doi. 10.1111/ejh.13835
By:
- Spicka, Ivan;
- Moreau, Philippe;
- Martin, Thomas G.;
- Facon, Thierry;
- Martinez, Gracia;
- Oriol, Albert;
- Koh, Youngil;
- Lim, Andrew;
- Mikala, Gabor;
- Rosiñol, Laura;
- Yağci, Münci;
- Cavo, Michele;
- Risse, Marie‐Laure;
- Asset, Gaëlle;
- Macé, Sandrine;
- van de Velde, Helgi;
- Yong, Kwee
Publication type:
Article
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.
Published in:
Cancer Medicine, 2023, v. 12, n. 20, p. 20332, doi. 10.1002/cam4.6619
By:
- Bisht, Kamlesh;
- Fukao, Taro;
- Chiron, Marielle;
- Richardson, Paul;
- Atanackovic, Djordje;
- Chini, Eduardo;
- Chng, Wee Joo;
- Van De Velde, Helgi;
- Malavasi, Fabio
Publication type:
Article
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
Published in:
Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753
By:
- Lesokhin, Alexander;
- LeBlanc, Richard;
- Dimopoulos, Meletios A.;
- Capra, Marcelo;
- Carlo‐Stella, Carmelo;
- Karlin, Lionel;
- Castilloux, Jean‐Francois;
- Forsberg, Peter;
- Parmar, Gurdeep;
- Tosikyan, Axel;
- Pour, Ludek;
- Ribrag, Vincent;
- Ribolla, Rossella;
- Abdallah, Al‐Ola;
- Le Roux, Nadia;
- Dong, Liyan;
- van de Velde, Helgi;
- Mayrargue, Laurent;
- Lépine, Lucie;
- Macé, Sandrine
Publication type:
Article
Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice.
Published in:
European Journal of Haematology, 2018, v. 101, n. 4, p. 556, doi. 10.1111/ejh.13147
By:
- Terpos, Evangelos;
- Katodritou, Eirini;
- de la Rubia, Javier;
- Hungria, Vania;
- Hulin, Cyrille;
- Roussou, Maria;
- Delforge, Michel;
- Bries, Greet;
- Stoppa, Anne‐Marie;
- Aagesen, Jesper;
- Sargin, Deniz;
- Belch, Andrew;
- Ahlberg, Lucia;
- Diels, Joris;
- Olie, Robert A.;
- Robinson, Jr, Don;
- Spencer, Mike;
- Potamianou, Anna;
- van de Velde, Helgi;
- Dimopoulos, Meletios A.
Publication type:
Article
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Published in:
European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
By:
- Delforge, Michel;
- Terpos, Evangelos;
- Richardson, Paul G.;
- Shpilberg, Ofer;
- Khuageva, Nuriet K.;
- Schlag, Rudolf;
- Dimopoulos, Meletios A.;
- Kropff, Martin;
- Spicka, Ivan;
- Petrucci, Maria T.;
- Samoilova, Olga S.;
- Mateos, Maria-Victoria;
- Magen-Nativ, Hila;
- Goldschmidt, Hartmut;
- Esseltine, Dixie-Lee;
- Ricci, Deborah S.;
- Liu, Kevin;
- Deraedt, William;
- Cakana, Andrew;
- van de Velde, Helgi
Publication type:
Article
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Published in:
European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
By:
- Dimopoulos, Meletios A.;
- Mateos, Maria-Victoria;
- Richardson, Paul G.;
- Schlag, Rudolf;
- Khuageva, Nuriet K.;
- Shpilberg, Ofer;
- Kropff, Martin;
- Spicka, Ivan;
- Palumbo, Antonio;
- Wu, Ka Lung;
- Esseltine, Dixie-Lee;
- Liu, Kevin;
- Deraedt, William;
- Cakana, Andrew;
- Van De Velde, Helgi;
- San Miguel, Jesús F.
Publication type:
Article
Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153]
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 424, doi. 10.1016/j.clml.2022.03.009
By:
- Moreau, Philippe;
- Parmar, Gurdeep;
- Prince, Miles;
- Ocio, Enrique M.;
- Karanes, Chatchada;
- Madan, Sumit;
- Oriol, Albert;
- Bories, Pierre;
- Delforgel, Michel;
- Gabrail, Nashat;
- Semiondi, Dorothee;
- Jia, Nan;
- Macé, Sandrine;
- Suzan, Florence;
- van de Velde, Helgi;
- Quach, Hang
Publication type:
Article
P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S159, doi. 10.1016/S2152-2650(21)02344-2
By:
- Špicka, Ivan;
- Moreau, Philippe;
- Martin, Thomas;
- Facon, Thierry;
- Martinez, Gracia;
- Oriol, A.;
- Youngil Koh;
- Lim, Andrew;
- Mikala, Gábor;
- Rosiñol, Laura;
- Münci Yagci;
- Cavo, Michele;
- Risse, Marie-Laure;
- Asset, Gaëlle;
- Macé, Sandrine;
- van de Velde, Helgi;
- Kwee Yong
Publication type:
Article
P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S152, doi. 10.1016/S2152-2650(21)02334-X
By:
- Moreau, Philippe;
- Parmar, Gurdeep;
- Prince, Miles;
- Ocio, Enrique;
- Karenes, Chatchada;
- Madan, Sumit;
- Oriol, A;
- Bories, Pierre;
- Delforge, Michel;
- Galbrail, Nashat;
- Semiond, Dorothee;
- Jia, Nan;
- Macé, Sandrine;
- Suzan, Florence;
- van de Velde, Helgi
Publication type:
Article
P-196: Isatuximab plus Carfilzomib and Dexamethasone in patients with relapsed Multiple Myeloma and soft-tissue Plasmacytomas: IKEMA subgroup analysis.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S145, doi. 10.1016/S2152-2650(21)02323-5
By:
- Hájek, Roman;
- Jelinek, Tomas;
- Moreau, Philippe;
- Martin, Thomas;
- Pour, Ludek;
- Mikala, Gábor;
- Symeonidis, Argiris;
- Bringhen, Sara;
- Rawlings, Andreea;
- Risse, Marie-Laure;
- van de Velde, Helgi;
- Špicka, Ivan
Publication type:
Article
MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S423, doi. 10.1016/S2152-2650(21)01948-0
By:
- Richardson, Paul G.;
- Perrot, Aurore;
- San-Miguel, Jesus;
- Beksac, Meral;
- Spicka, Ivan;
- Leleu, Xavier;
- Schjesvold, Fredrik;
- Moreau, Philippe;
- Dimopoulos, Meletios A.;
- Huang, Jeffrey Shang-Yi;
- Minarik, Jiri;
- Cavo, Michele;
- Prince, H Miles;
- Cheng Zheng;
- Dubin, Franck;
- van De Velde, Helgi;
- Anderson, Kenneth C.
Publication type:
Article
Poster: MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01572-X
By:
- Richardson, Paul G.;
- Perrot, Aurore;
- San-Miguel, Jesus;
- Beksac, Meral;
- Spicka, Ivan;
- Leleu, Xavier;
- Schjesvold, Fredrik;
- Moreau, Philippe;
- Dimopoulos, Meletios A.;
- Huang, Jeffrey Shang-Yi;
- Minarik, Jiri;
- Cavo, Michele;
- Prince, H Miles;
- Zheng, Cheng;
- Dubin, Franck;
- van De Velde, Helgi;
- Anderson, Kenneth C
Publication type:
Article
ICARIA-MM study: efficacy analysis according to prior lines of treatment.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e245, doi. 10.1016/j.clml.2019.09.407
By:
- Bringhen, Sara;
- Attal, Michel;
- Pour, Ludek;
- Vorobyev, Vladimir;
- Vural, Filiz;
- Warzocha, Krzysztof;
- Benboubker, Lofti;
- Koh, Youngil;
- Maisnar, Vladimir;
- KARLIN, Lionel;
- Pavic, Michel;
- Campana, Frank;
- Charpentier, Eric;
- Menas, Fatima;
- van de Velde, Helgi;
- Richardson, Paul G.
Publication type:
Article
Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e254, doi. 10.1016/j.clml.2019.09.420
By:
- Dimopoulos, Meletios A.;
- Leleu, Xavier;
- Moreau, Philippe;
- Attal, Michel;
- Richardson, Paul G.;
- Liberati, Anna Marina;
- Harrison, Simon J.;
- Prince, H. Miles;
- Ocio, Enrique M.;
- Assadourian, Sylvie;
- Campana, Frank;
- Malinge, Laure;
- van de Velde, Helgi;
- Yong, Kwee
Publication type:
Article
Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e33, doi. 10.1016/j.clml.2019.09.049
By:
- Harrison, Simon J.;
- Richardson, Paul G.;
- Alegre, Adrian;
- Simpson, David;
- Wang, Ming Chung;
- Spencer, Andrew;
- Delimpasi, Sossana;
- Hulin, Cyrille;
- Sunami, Kazutaka;
- Facon, Thierry;
- Vlummens, Philip;
- Yong, Kwee;
- Campana, Frank;
- Inchauspé, Marlène;
- Macé, Sandrine;
- Risse, Marie-Laure;
- van de Velde, Helgi;
- Attal, Michel
Publication type:
Article
The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685).
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S337, doi. 10.1016/j.clml.2017.07.153
By:
- San Miguel, Jesus;
- Echeveste Gutierrez, Maria Asunción;
- Špicka, Ivan;
- Mateos, María-Victoria;
- Song, Kevin;
- Craig, Michael;
- Bladé, Joan;
- Hájek, Roman;
- Chen, Christine;
- Gupta, Neeraj;
- Byrne, Catriona;
- Lu, Vickie;
- van de Velde, Helgi;
- Lonial, Sagar
Publication type:
Article
Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e67, doi. 10.1016/j.clml.2017.03.121
By:
- Hou, Jian;
- Jin, Jie;
- Xu, Yan;
- Wu, Depei;
- Ke, Xiaoyan;
- Daobin, Zhou;
- Lu, Jin;
- Du, Xin;
- Chen, Xiequn;
- Li, Junmin;
- Liu, Jing;
- Gupta, Neeraj;
- Hanley, Michael;
- Li, Hongmei;
- Hua, Zhaowei;
- Wang, Bingxia;
- Zhang, Xiaoquan;
- Wang, Hui;
- van de Velde, Helgi;
- Richardson, Paul
Publication type:
Article
Late vs Early Response and Depth of Response Are Associated with Improved Outcomes: Post-hoc Analysis of Phase 3 TOURMALINE-MM1 Trial (NCT01564537) in Relapsed/Refractory Multiple Myeloma (RRMM).
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e124, doi. 10.1016/j.clml.2017.03.226
By:
- Garderet, Laurent;
- Laubach, Jacob;
- Stoppa, Anne-Marie;
- Parameswaran, Hari;
- Cavo, Michele;
- Ludwig, Heinz;
- Mateos, Maria-Victoria;
- Luptakova, Katarina;
- Lin, Jianchang;
- van de Velde, Helgi;
- Berg, Deborah;
- Moreau, Philippe;
- Richardson, Paul
Publication type:
Article
Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Published in:
CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 6, p. 766, doi. 10.1002/psp4.12789
By:
- Rachedi, Fatiha;
- Koiwai, Kimiko;
- Gaudel‐Dedieu, Nadia;
- Sebastien, Bernard;
- Thai, Hoai‐Thu;
- Brillac, Claire;
- Fau, Jean Baptiste;
- Nguyen, Laurent;
- van de Velde, Helgi;
- Veyrat‐Follet, Christine;
- Semiond, Dorothée
Publication type:
Article
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
Published in:
CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 928, doi. 10.1002/psp4.12666
By:
- Koiwai, Kimiko;
- El‐Cheikh, Raouf;
- Thai, Hoai‐Thu;
- Brillac, Claire;
- Fau, Jean‐Baptiste;
- Veyrat‐Follet, Christine;
- Risse, Marie‐Laure;
- van de Velde, Helgi;
- Semiond, Dorothée;
- Nguyen, Laurent
Publication type:
Article
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Published in:
2021
By:
- Richardson, Paul G.;
- Facon, Thierry;
- Bensinger, William I.;
- Leleu, Xavier;
- Campana, Frank;
- Macé, Sandrine;
- Chiron, Marielle;
- van de Velde, Helgi;
- Mikhael, Joseph
Publication type:
Letter
Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma.
Published in:
Clinical Pharmacokinetics, 2012, v. 51, n. 12, p. 823, doi. 10.1007/s40262-012-0010-0
By:
- Moreau, Philippe;
- Karamanesht, Ievgenii I.;
- Donmikova, Natalia;
- Kyselyova, Maryna Y.;
- Vilchevska, Kateryna V.;
- Doronin, Vadim A.;
- Schmidt, Alexander;
- Hulin, Cyrille;
- Leleu, Xavier;
- Esseltine, Dixie-Lee;
- Venkatakrishnan, Karthik;
- Skee, Donna;
- Huaibao Feng;
- Girgis, Suzette;
- Cakana, Andrew;
- van de Velde, Helgi;
- Deraedt, William;
- Facon, Thierry
Publication type:
Article
Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.
Published in:
Clinical Pharmacokinetics, 2011, v. 50, n. 12, p. 781, doi. 10.2165/11594410-000000000-00000
By:
- Hellmann, Andrzej;
- Rule, Simon;
- Walewski, Jan;
- Shpilberg, Ofer;
- Huaibao Feng;
- de Velde, Helgi van;
- Patel, Hamina;
- Skee, Donna M.;
- Girgis, Suzette;
- Louw, Vernon J.
Publication type:
Article
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Published in:
American Journal of Hematology, 2015, v. 90, n. 5, p. E86, doi. 10.1002/ajh.23967
By:
- Harrison, Simon J.;
- Quach, Hang;
- Link, Emma;
- Feng, Huaibao;
- Dean, Joanne;
- Copeman, Michael;
- Van De Velde, Helgi;
- Schwarer, Anthony;
- Baker, Bartrum;
- Spencer, Andrew;
- Catalano, John;
- Campbell, Philip;
- Augustson, Bradley;
- Romeril, Ken;
- Prince, Henry Miles
Publication type:
Article
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Published in:
American Journal of Hematology, 2015, v. 90, n. 4, p. 314, doi. 10.1002/ajh.23933
By:
- Mateos, María Victoria;
- Richardson, Paul G.;
- Dimopoulos, Meletios A.;
- Palumbo, Antonio;
- Anderson, Kenneth C.;
- Shi, Hongliang;
- Elliott, Jennifer;
- Dow, Edward;
- van de Velde, Helgi;
- Niculescu, Liviu;
- San Miguel, Jesús F.
Publication type:
Article
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Published in:
American Journal of Hematology, 2015, v. 90, n. 1, p. 42, doi. 10.1002/ajh.23868
By:
- Orlowski, Robert Z.;
- Gercheva, Liana;
- Williams, Cathy;
- Sutherland, Heather;
- Robak, Tadeusz;
- Masszi, Tamás;
- Goranova-Marinova, Vesselina;
- Dimopoulos, Meletios A.;
- Cavenagh, James D.;
- Špička, Ivan;
- Maiolino, Angelo;
- Suvorov, Alexander;
- Bladé, Joan;
- Samoylova, Olga;
- Puchalski, Thomas A.;
- Reddy, Manjula;
- Bandekar, Rajesh;
- van de Velde, Helgi;
- Xie, Hong;
- Rossi, Jean-Franςois
Publication type:
Article
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.
Published in:
Cells (2073-4409), 2024, v. 13, n. 10, p. 879, doi. 10.3390/cells13100879
By:
- Grab, Anna Luise;
- Kim, Peter S.;
- John, Lukas;
- Bisht, Kamlesh;
- Wang, Hongfang;
- Baumann, Anja;
- Van de Velde, Helgi;
- Sarkar, Irene;
- Shome, Debarati;
- Reichert, Philipp;
- Manta, Calin;
- Gryzik, Stefanie;
- Reijmers, Rogier M.;
- Weinhold, Niels;
- Raab, Marc S.
Publication type:
Article
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Published in:
Cells (2073-4409), 2019, v. 8, n. 12, p. 1522, doi. 10.3390/cells8121522
By:
- Martin, Thomas G.;
- Corzo, Kathryn;
- Chiron, Marielle;
- van de Velde, Helgi;
- Abbadessa, Giovanni;
- Campana, Frank;
- Solanki, Malini;
- Meng, Robin;
- Lee, Helen;
- Wiederschain, Dmitri;
- Zhu, Chen;
- Rak, Alexey;
- Anderson, Kenneth C.
Publication type:
Article
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.
Published in:
Journal of Blood Medicine, 2017, v. 8, p. 107, doi. 10.2147/JBM.S102328
By:
- A;
- Richardson, Paul G.;
- Kumar, Shaji;
- Laubach, Jacob P.;
- Paba-Prada, Claudia;
- Gupta, Neeraj;
- Berg, Deborah;
- van de Velde, Helgi;
- Moreau, Philippe
Publication type:
Article
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Published in:
2017
By:
- Gupta, Neeraj;
- Diderichsen, Paul;
- Hanley, Michael;
- Berg, Deborah;
- de Velde, Helgi;
- Harvey, R.;
- Venkatakrishnan, Karthik;
- Diderichsen, Paul M;
- Hanley, Michael J;
- van de Velde, Helgi;
- Harvey, R Donald
Publication type:
journal article
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Published in:
Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0501-4
By:
- Jian Hou;
- Jie Jin;
- Yan Xu;
- Depei Wu;
- Xiaoyan Ke;
- Daobin Zhou;
- Jin Lu;
- Xin Du;
- Xiequn Chen;
- Junmin Li;
- Jing Liu;
- Gupta, Neeraj;
- Hanley, Michael J.;
- Hongmei Li;
- Zhaowei Hua;
- Bingxia Wang;
- Xiaoquan Zhang;
- Hui Wang;
- van de Velde, Helgi;
- Richardson, Paul G.
Publication type:
Article
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
Published in:
British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x
By:
- Richardson, Paul;
- Schlag, Rudolf;
- Khuageva, Nuriet;
- Dimopoulos, Meletios;
- Shpilberg, Ofer;
- Kropff, Martin;
- Vekemans, Marie-Christiane;
- Petrucci, Maria Teresa;
- Rossiev, Viktor;
- Hou, Jian;
- Robak, Tadeusz;
- Mateos, Maria-Victoria;
- Anderson, Kenneth;
- Esseltine, Dixie-Lee;
- Cakana, Andrew;
- Liu, Kevin;
- Deraedt, William;
- van de Velde, Helgi;
- San Miguel, Jesús F.
Publication type:
Article
Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.
Published in:
OncoTargets & Therapy, 2018, v. 11, p. 3869, doi. 10.2147/OTT.S150339
By:
- Jin, Jie;
- Okamoto, Rumiko;
- Yoon, Sung-Soo;
- Shih, Lee-Yung;
- Zhu, Jun;
- Liu, Ting;
- Hong, Xiaonan;
- Pei, Lixia;
- Rooney, Brendan;
- van de Velde, Helgi;
- Huang, Huiqiang
Publication type:
Article

Found: 41